Table 3.

Crude and adjusted HRs of MACE in patients with VV compared with the matched control cohort during the follow-up period

Cohort all (n=22 386)	Crude HR (95% CI)	P value	Adjusted HR (95% CI)†	P value
Overall analysis
VV	2.08 (1.91 to 2.25)	<0.0001*	2.05 (1.89 to 2.23)	<0.0001*
Controls	1(reference)		1(reference)
Stratified analysis
Age (years)
<65 (years)
VV	2.21 (1.95 to 2.5)	<0.0001*	2.17 (1.92 to 2.46)	<0.0001*
Controls	1(reference)		1(reference)
≧65 (years)
VV	1.98 (1.78 to 2.21)	<0.0001*	1.96 (1.76 to 2.18)	<0.0001*
Controls	1(reference)		1(reference)
Gender
Male
VV	2.35 (2.09 to 2.65)	<0.0001*	2.32 (2.06 to 2.62)	<0.0001*
Controls	1(reference)		1(reference)
Female
VV	1.87 (1.67 to 2.09)	<0.0001*	1.85 (1.66 to 2.07)	<0.0001*
Controls	1(reference)		1(reference)
Hypertension
VV	1.65 (1.42 to 1.92)	<0.0001*	1.62 (1.39 to 1.89)	<0.0001*
Controls	1(reference)		1(reference)
Diabetes
VV	1.4 (1.11 to 1.76)	0.0042*	1.37 (1.08 to 1.72)	0.0081
Controls	1(reference)		1(reference)
Hyperlipidaemia
VV	1.5 (1.03 to 2.17)	0.0353*	1.56 (1.07 to 2.29)	0.0224
Controls	1(reference)		1(reference)
Coronary artery disease
VV	1.93 (1.38 to 2.7)	0.0001*	1.99 (1.41 to 2.82)	0.0001*
Controls	1(reference)		1(reference)

*P<0.05.

†Adjusted for chronic obstructive pulmonary disease, cancer, atrial fibrillation, heart failure, ischaemic heart disease, chronic renal insufficiency.

MACE, major adverse cardiovascular event; VV, varicose veins.